Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.38 |
| ▸ | FCER2 | P06734 | 2/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 4/20 | 0.38 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.34 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.34 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.34 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.34 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.34 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.34 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417248 | 0.95 | MMP1 (0.41) | LMNAMMP1FCER2ADAM17MMP9 | |
| SCHEMBL7363465 | 0.95 | LMNA (0.37) | LMNAMMP1FCER2ADAM17MMP9 | |
| SCHEMBL6411770 | 0.90 | MMP1 (0.44) | LMNAMMP1FCER2ADAM17MMP9 | |
| SCHEMBL7360690 | 0.87 | FCER2 (0.41) | LMNAMMP1FCER2MMP9MMP2 | |
| SCHEMBL6420230 | 0.81 | LMNA (0.41) | LMNAMMP1MMP9MMP2MMP8 | |
| SCHEMBL7365448 | 0.81 | MMP1 (0.55) | MMP1FCER2ADAM17MMP9MMP2 | |
| SCHEMBL8749878 | 0.76 | MMP1 (0.57) | MMP1FCER2ADAM17MMP9MMP2 | |
| SCHEMBL7391172 | 0.76 | MMP1 (0.47) | MMP1FCER2ADAM17MMP9MMP2 | |
| SCHEMBL6415490 | 0.74 | MMP1 (0.47) | MMP1FCER2ADAM17MMP9MMP2 | |
| SCHEMBL6412867 | 0.74 | MMP3 (0.51) | MMP1FCER2ADAM17MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5691382-A | ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-11-25 | — | — | US | claimed |
| EP-0667770-B1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARM (GB) | 1997-03-19 | — | — | EP | claimed |
| EP-0667770-A1 | INHIBITION OF TNF PRODUCTION. | BRITISH BIOTECH PHARM (GB) | 1995-08-23 | — | — | EP | claimed |
| WO-1994010990-A1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-05-26 | — | — | WO | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5691382-A | ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-11-25 | — | — | US | disclosed |
| EP-0667770-B1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARM (GB) | 1997-03-19 | — | — | EP | disclosed |
| EP-0667770-A1 | INHIBITION OF TNF PRODUCTION. | BRITISH BIOTECH PHARM (GB) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994010990-A1 | INHIBITION OF TNF PRODUCTION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | LMNA 1874/4885MMP1 20/4885FCER2 4226/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | LMNA 1874/4885MMP1 20/4885FCER2 4226/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | LMNA 1874/4885MMP1 20/4885FCER2 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.